Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
Kroschinsky F, Middeke JM, Janz M, Lenz G, Witzens-Harig M, Bouabdallah R, La Rosée P, Viardot A, Salles G, Kim SJ, Kim TM, Ottmann O, Chromik J, Quinson AM, von Wangenheim U, Burkard U, Berk A, Schmitz N. Kroschinsky F, et al. Among authors: chromik j. Invest New Drugs. 2020 Oct;38(5):1472-1482. doi: 10.1007/s10637-020-00916-3. Epub 2020 Mar 14. Invest New Drugs. 2020. PMID: 32172489 Free PMC article. Clinical Trial.
Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
Kroschinsky F, Middeke JM, Janz M, Lenz G, Witzens-Harig M, Bouabdallah R, La Rosée P, Viardot A, Salles G, Kim SJ, Kim TM, Ottmann O, Chromik J, Quinson AM, von Wangenheim U, Burkard U, Berk A, Schmitz N. Kroschinsky F, et al. Among authors: chromik j. Invest New Drugs. 2021 Feb;39(1):283-284. doi: 10.1007/s10637-020-00949-8. Invest New Drugs. 2021. PMID: 32474843 Free PMC article. No abstract available.
Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B cell non-Hodgkin lymphoma.
Kroschinsky F, Middeke JM, Janz M, Lenz G, Witzens-Harig M, Bouabdallah R, La Rosée P, Viardot A, Salles G, Kim SJ, Kim TM, Ottmann O, Chromik J, Quinson AM, von Wangenheim U, Burkard U, Berk A, Schmitz N. Kroschinsky F, et al. Among authors: chromik j. Invest New Drugs. 2021 Feb;39(1):285-286. doi: 10.1007/s10637-020-00964-9. Invest New Drugs. 2021. PMID: 32578153 Free PMC article. No abstract available.
Low-dose melphalan in elderly patients with relapsed or refractory acute myeloid leukemia: A well-tolerated and effective treatment after hypomethylating-agent failure.
Stratmann J, van Kann E, Rummelt C, Koschade S, Röllig C, Lübbert M, Schaich M, Parmentier S, Sebastian M, Chromik J, Becker von Rose A, Ballo O, Steffen B, Serve H, Brandts C, Shaid S. Stratmann J, et al. Among authors: chromik j. Leuk Res. 2019 Oct;85:106192. doi: 10.1016/j.leukres.2019.106192. Epub 2019 Aug 10. Leuk Res. 2019. PMID: 31445469
A Phase II study of selinexor plus cytarabine and idarubicin in patients with relapsed/refractory acute myeloid leukaemia.
Fiedler W, Chromik J, Amberg S, Kebenko M, Thol F, Schlipfenbacher V, Christine Wilke A, Modemann F, Janning M, Serve H, Ganser A, Bokemeyer C, Theile S, Deppermann U, Kranich AL, Heuser M. Fiedler W, et al. Among authors: chromik j. Br J Haematol. 2020 Aug;190(3):e169-e173. doi: 10.1111/bjh.16804. Epub 2020 Jun 9. Br J Haematol. 2020. PMID: 32515072 Free article. Clinical Trial. No abstract available.
Molecular response patterns in relapsed/refractory AML patients treated with selinexor and chemotherapy.
Klement P, Fiedler W, Gabdoulline R, Dallmann LK, Wienecke CP, Schiller J, Kandziora C, Teich K, Heida B, Büttner K, Brandes M, Funke C, Wichmann M, Othman B, Chromik J, Amberg S, Kebenko M, Schlipfenbacher V, Wilke AC, Modemann F, Janning M, Serve H, Bokemeyer C, Theile S, Deppermann U, Kranich AL, Ganser A, Thol F, Heuser M. Klement P, et al. Among authors: chromik j. Ann Hematol. 2023 Feb;102(2):323-328. doi: 10.1007/s00277-022-05075-4. Epub 2022 Dec 28. Ann Hematol. 2023. PMID: 36576532 Free PMC article.
Volasertib as a monotherapy or in combination with azacitidine in patients with myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia: summary of three phase I studies.
Platzbecker U, Chromik J, Krönke J, Handa H, Strickland S, Miyazaki Y, Wermke M, Sakamoto W, Tachibana Y, Taube T, Germing U. Platzbecker U, et al. Among authors: chromik j. BMC Cancer. 2022 May 21;22(1):569. doi: 10.1186/s12885-022-09622-0. BMC Cancer. 2022. PMID: 35597904 Free PMC article.
Long-Term Efficacy and Safety of Luspatercept for Anemia Treatment in Patients With Lower-Risk Myelodysplastic Syndromes: The Phase II PACE-MDS Study.
Platzbecker U, Götze KS, Kiewe P, Germing U, Mayer K, Radsak M, Wolff T, Chromik J, Sockel K, Oelschlägel U, Haase D, Illmer T, Al-Ali HK, Silling G, Reynolds JG, Zhang X, Attie KM, Shetty JK, Giagounidis A. Platzbecker U, et al. Among authors: chromik j. J Clin Oncol. 2022 Nov 20;40(33):3800-3807. doi: 10.1200/JCO.21.02476. Epub 2022 Aug 23. J Clin Oncol. 2022. PMID: 35998303 Free PMC article. Clinical Trial.
Phase 1 study of JNJ-64619178, a protein arginine methyltransferase 5 inhibitor, in patients with lower-risk myelodysplastic syndromes.
Haque T, Cadenas FL, Xicoy B, Alfonso-Pierola A, Platzbecker U, Avivi I, Brunner AM, Chromik J, Morillo D, Patel MR, Falantes J, Leitch HA, Germing U, Preis M, Lenox L, Lauring J, Brown RJ, Kalota A, Mehta J, Pastore F, Gu J, Mistry P, Valcárcel D. Haque T, et al. Among authors: chromik j. Leuk Res. 2023 Nov;134:107390. doi: 10.1016/j.leukres.2023.107390. Epub 2023 Sep 20. Leuk Res. 2023. PMID: 37776843 Clinical Trial.
29 results